Skip to main content

Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?

Videos

Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.

Related Items